Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Darifenacin	Constipation	Country	Restricted maximum likelihood	-0.01	0.04	0.71
Study	Darifenacin	Constipation	Intention to treat	Restricted maximum likelihood	0.04	0.06	0.5
Treatment	Darifenacin	Constipation	Daily dose	Restricted maximum likelihood	0	0	0.43
Treatment	Darifenacin	Constipation	Weeks of treatment	Restricted maximum likelihood	0.01	0.01	0.63
Women	Darifenacin	Constipation	% of women	Restricted maximum likelihood	0	0	0.47
Women	Darifenacin	Constipation	Daily UI	Restricted maximum likelihood	0.08	0.11	0.5
Women	Darifenacin	Constipation	Inclusion of minorities	Restricted maximum likelihood	-0.08	0.11	0.5
Women	Darifenacin	Constipation	Inclusion of mixed UI	Restricted maximum likelihood	-0.13	0.06	0.08
Women	Darifenacin	Constipation	Inclusion of prior failures	Restricted maximum likelihood	0.04	0.04	0.41
Women	Darifenacin	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.11	0.06	0.15
Women	Darifenacin	Constipation	Rate in placebo group	Restricted maximum likelihood	-1.62	1.86	0.42
Study	Darifenacin	Dry mouth	Adequate randomization	Restricted maximum likelihood	0.1	0.07	0.23
Study	Darifenacin	Dry mouth	Country	Restricted maximum likelihood	0	0.07	0.96
Study	Darifenacin	Dry mouth	Intention to treat	Restricted maximum likelihood	0.1	0.07	0.23
Treatment	Darifenacin	Dry mouth	Daily dose	Restricted maximum likelihood	0.01	0.01	0.24
Treatment	Darifenacin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	0.01	0.01	0.3
Women	Darifenacin	Dry mouth	% of women	Restricted maximum likelihood	0.01	0.01	0.24
Women	Darifenacin	Dry mouth	Daily UI	Restricted maximum likelihood	0.2	0.15	0.23

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Darifenacin	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.2	0.15	0.23
Women	Darifenacin	Dry mouth	Inclusion of mixed UI*	Restricted maximum likelihood	-0.26	0.1	0.04
Women	Darifenacin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	0.09	0.07	0.26
Women	Darifenacin	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.13	0.16	0.47
Women	Darifenacin	Dry mouth	Rate in placebo group	Restricted maximum likelihood	0.59	3.01	0.85
Study	Darifenacin	Dyspepsia	Adequate randomization	Restricted maximum likelihood	0.02	0.01	0.23
Study	Darifenacin	Dyspepsia	Intention to treat	Restricted maximum likelihood	0.02	0.01	0.23
Treatment	Darifenacin	Dyspepsia	Daily dose	Restricted maximum likelihood	0	0	0.87
Treatment	Darifenacin	Dyspepsia	Weeks of treatment	Restricted maximum likelihood	0	0	0.54
Women	Darifenacin	Dyspepsia	% of women	Restricted maximum likelihood	0	0	0.25
Women	Darifenacin	Dyspepsia	Daily UI	Restricted maximum likelihood	0.03	0.02	0.23
Women	Darifenacin	Dyspepsia	Inclusion of minorities	Restricted maximum likelihood	-0.03	0.02	0.23
Women	Darifenacin	Dyspepsia	Inclusion of mixed UI	Restricted maximum likelihood	-0.03	0.02	0.22
Women	Darifenacin	Dyspepsia	Inclusion of prior failures	Restricted maximum likelihood	0.02	0.01	0.23
Women	Darifenacin	Dyspepsia	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.01	0.03	0.84
Women	Darifenacin	Dyspepsia	Rate in placebo group*	Restricted maximum likelihood	-3.54	1.3	0.04
Study	Darifenacin	Improvement in UI	Country	Restricted maximum likelihood	0	0.01	0.98
Study	Darifenacin	Improvement in UI	Intention to treat	Restricted maximum likelihood	-0.01	0.03	0.83

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Darifenacin	Improvement in UI	Daily dose	Restricted maximum likelihood	0	0.01	0.82
Women	Darifenacin	Improvement in UI	% of women	Restricted maximum likelihood	0	0.01	0.83
Women	Darifenacin	Improvement in UI	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.02	0.07	0.83
Study	Fesoterodine	Constipation	Adequate randomization	Restricted maximum likelihood	-0.01	0.02	0.51
Study	Fesoterodine	Constipation	Allocation concealment	Restricted maximum likelihood	-0.01	0.02	0.52
Study	Fesoterodine	Constipation	Conflict of interest	Restricted maximum likelihood	-0.02	0.04	0.61
Study	Fesoterodine	Constipation	Country	Restricted maximum likelihood	0.01	0.02	0.73
Study	Fesoterodine	Constipation	Intention to treat	Restricted maximum likelihood	0.06	0.04	0.14
Study	Fesoterodine	Constipation	Justification of sample size	Restricted maximum likelihood	0.04	0.02	0.16
Treatment	Fesoterodine	Constipation	Daily dose	Restricted maximum likelihood	0	0.01	1
Women	Fesoterodine	Constipation	% of women*	Restricted maximum likelihood	-0.01	0	0.04
Women	Fesoterodine	Constipation	Inclusion of mixed UI	Restricted maximum likelihood	0.05	0.05	0.3
Women	Fesoterodine	Constipation	Inclusion of prior failures	Restricted maximum likelihood	-0.03	0.04	0.48
Women	Fesoterodine	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.02	0.04	0.64
Women	Fesoterodine	Constipation	Rate in placebo group	Restricted maximum likelihood	-0.49	1.62	0.77
Study	Fesoterodine	Discontinuation due to failure	Adequate randomization	Restricted maximum likelihood	0.01	0.01	0.33
Study	Fesoterodine	Discontinuation due to failure	Allocation concealment	Restricted maximum likelihood	0	0.01	1
Study	Fesoterodine	Discontinuation due to failure	Conflict of interest	Restricted maximum likelihood	0	0.02	1

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Fesoterodine	Discontinuation due to failure	Country	Restricted maximum likelihood	0	0.01	0.78
Study	Fesoterodine	Discontinuation due to failure	Justification of sample size	Restricted maximum likelihood	0	0.02	1
Women	Fesoterodine	Discontinuation due to failure	% of women	Restricted maximum likelihood	-0.01	0	0.2
Women	Fesoterodine	Discontinuation due to failure	Inclusion of minorities	Restricted maximum likelihood	0	0.02	1
Women	Fesoterodine	Discontinuation due to failure	Inclusion of prior failures	Restricted maximum likelihood	0.02	0.02	0.44
Women	Fesoterodine	Discontinuation due to failure	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.02	0.02	0.41
Women	Fesoterodine	Discontinuation due to failure	Rate in placebo group	Restricted maximum likelihood	-1.36	0.44	0.09
Study	Fesoterodine	Dry eye	Adequate randomization	Restricted maximum likelihood	0.01	0	0.22
Study	Fesoterodine	Dry eye	Allocation concealment	Restricted maximum likelihood	0.01	0.01	0.18
Study	Fesoterodine	Dry eye	Conflict of interest	Restricted maximum likelihood	0.01	0.01	0.27
Study	Fesoterodine	Dry eye	Country	Restricted maximum likelihood	0	0.01	0.83
Study	Fesoterodine	Dry eye	Intention to treat	Restricted maximum likelihood	-0.02	0.01	0.17
Study	Fesoterodine	Dry eye	Justification of sample size	Restricted maximum likelihood	-0.01	0.01	0.29
Treatment	Fesoterodine	Dry eye	Daily dose	Restricted maximum likelihood	0.01	0	0.22
Women	Fesoterodine	Dry eye	% of women	Restricted maximum likelihood	0	0	0.35
Women	Fesoterodine	Dry eye	Inclusion of minorities	Restricted maximum likelihood	0.02	0.01	0.18
Women	Fesoterodine	Dry eye	Inclusion of prior failures	Restricted maximum likelihood	0.02	0.01	0.17
Women	Fesoterodine	Dry eye	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.02	0.01	0.18

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Fesoterodine	Dry eye	Rate in placebo group	Restricted maximum likelihood	-0.96	0.6	0.17
Study	Fesoterodine	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.005	0.020	0.822
Study	Fesoterodine	Dry mouth	Adequate randomization	Restricted maximum likelihood	0.001	0.018	0.95
Study	Fesoterodine	Dry mouth	Conflict of interest	Restricted maximum likelihood	0.005	0.041	0.915
Study	Fesoterodine	Dry mouth	Intention to treat	Restricted maximum likelihood	0.016	0.043	0.718
Study	Fesoterodine	Dry mouth	Justification of sample size	Restricted maximum likelihood	0.009	0.024	0.742
Treatment	Fesoterodine	Dry mouth	Daily dose*	Restricted maximum likelihood	0.019	0.007	0.023
Women	Fesoterodine	Dry mouth	Country	Restricted maximum likelihood	-0.001	0.022	0.97
Women	Fesoterodine	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.001	0.041	0.98
Women	Fesoterodine	Dry mouth	% of women	Restricted maximum likelihood	-0.000	0.003	0.902
Women	Fesoterodine	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.010	0.042	0.822
Women	Fesoterodine	Dry mouth	Rate in placebo group	Restricted maximum likelihood	-0.789	1.574	0.63
Women	Fesoterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.017	0.0401	0.675
Study	Fesoterodine	Headache	Allocation concealment	Restricted maximum likelihood	0.001	0.012	0.944
Study	Fesoterodine	Headache	Adequate randomization	Restricted maximum likelihood	-0.002	0.007	0.806
Study	Fesoterodine	Headache	Conflict of interest	Restricted maximum likelihood	0.003	0.016	0.856
Study	Fesoterodine	Headache	Intention to treat	Restricted maximum likelihood	0.027	0.012	0.054
Study	Fesoterodine	Headache	Justification of sample size	Restricted maximum likelihood	0.014	0.006	0.053

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Fesoterodine	Headache	Daily dose	Restricted maximum likelihood	-0.004	0.004	0.37
Women	Fesoterodine	Headache	Country*	Restricted maximum likelihood	-0.015	0.005	0.029
Women	Fesoterodine	Headache	Inclusion of prior failures	Restricted maximum likelihood	-0.004	0.017	0.837
Women	Fesoterodine	Headache	% of women	Restricted maximum likelihood	-0.001	0.001	0.203
Women	Fesoterodine	Headache	Inclusion of minorities	Restricted maximum likelihood	0.002	0.025	0.944
Women	Fesoterodine	Headache	Rate in placebo group	Restricted maximum likelihood	-0.104	0.192	0.605
Women	Fesoterodine	Headache	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.027	0.013	0.069
Study	Oxybutynin	Improvement in UI	Allocation concealment	Restricted maximum likelihood	-0.004	0.036	0.906
Study	Oxybutynin	Improvement in UI	Adequate randomization	Restricted maximum likelihood	-0.029	0.041	0.507
Study	Oxybutynin	Improvement in UI	Intention to treat	Restricted maximum likelihood	0.011	0.041	0.794
Study	Oxybutynin	Improvement in UI	Justification of sample size	Restricted maximum likelihood	-0.048	0.044	0.306
Treatment	Oxybutynin	Improvement in UI	Daily dose	Restricted maximum likelihood	-0.006	0.010	0.55
Treatment	Oxybutynin	Improvement in UI	Weeks of treatment	Restricted maximum likelihood	-0.009	0.011	0.466
Women	Oxybutynin	Improvement in UI	Country	Restricted maximum likelihood	-0.058	0.028	0.076
Women	Oxybutynin	Improvement in UI	Daily UI	Restricted maximum likelihood	-0.074	0.076	0.363
Women	Oxybutynin	Improvement in UI	Inclusion of prior failures	Restricted maximum likelihood	0.031	0.057	0.597
Women	Oxybutynin	Improvement in UI	% of women	Restricted maximum likelihood	-0.001	0.003	0.74
Women	Oxybutynin	Improvement in UI	Rate in placebo group	Restricted maximum likelihood	0.068	0.178	0.715

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Oxybutynin	Improvement in UI	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.034	0.058	0.57
Study	Oxybutynin	Adverse effects	Country	Restricted maximum likelihood	0.01	0.15	0.94
Study	Oxybutynin	Adverse effects	Justification of sample size	Restricted maximum likelihood	-0.14	0.07	0.29
Treatment	Oxybutynin	Adverse effects	Daily dose	Restricted maximum likelihood	0.05	0.02	0.32
Treatment	Oxybutynin	Adverse effects	Weeks of treatment	Restricted maximum likelihood	-0.04	0.02	0.29
Women	Oxybutynin	Adverse effects	% of women	Restricted maximum likelihood	0	0.01	0.91
Women	Oxybutynin	Adverse effects	Daily UI	Restricted maximum likelihood	-0.28	0.14	0.29
Women	Oxybutynin	Adverse effects	Inclusion of minorities	Restricted maximum likelihood	-0.24	0.18	0.41
Women	Oxybutynin	Adverse effects	Inclusion of mixed UI	Restricted maximum likelihood	-0.12	0.09	0.41
Women	Oxybutynin	Adverse effects	Rate in placebo group	Restricted maximum likelihood	0.7	0.52	0.41
Study	Oxybutynin	Dry mouth	Adequate randomization	Restricted maximum likelihood	-0.06	0.06	0.38
Study	Oxybutynin	Dry mouth	Allocation concealment	Restricted maximum likelihood	0.1	0.1	0.33
Study	Oxybutynin	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.27	0.19	0.19
Study	Oxybutynin	Dry mouth	Country	Restricted maximum likelihood	-0.03	0.07	0.67
Study	Oxybutynin	Dry mouth	Intention to treat	Restricted maximum likelihood	0.07	0.08	0.37
Study	Oxybutynin	Dry mouth	Justification of sample size	Restricted maximum likelihood	-0.12	0.09	0.24
Treatment	Oxybutynin	Dry mouth	Daily dose	Restricted maximum likelihood	0.02	0.01	0.21
Treatment	Oxybutynin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.01	0.02	0.67

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Oxybutynin	Dry mouth	% of women	Restricted maximum likelihood	-0.01	0.01	0.39
Women	Oxybutynin	Dry mouth	Daily UI	Restricted maximum likelihood	-0.11	0.16	0.52
Women	Oxybutynin	Dry mouth	Inclusion of minorities*	Restricted maximum likelihood	-0.43	0.12	0.01
Women	Oxybutynin	Dry mouth	Inclusion of mixed UI	Restricted maximum likelihood	-0.14	0.08	0.09
Women	Oxybutynin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.09	0.13	0.48
Women	Oxybutynin	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.24	0.19	0.24
Women	Oxybutynin	Dry mouth	Rate in placebo group	Restricted maximum likelihood	-0.08	0.32	0.81
Study	Oxybutynin	Failure	Adequate randomization	Restricted maximum likelihood	-0.04	0.04	0.41
Study	Oxybutynin	Failure	Allocation concealment	Restricted maximum likelihood	-0.03	0.06	0.7
Study	Oxybutynin	Failure	Country	Restricted maximum likelihood	0.02	0.06	0.76
Study	Oxybutynin	Failure	Intention to treat	Restricted maximum likelihood	0.1	0.04	0.06
Study	Oxybutynin	Failure	Justification of sample size	Restricted maximum likelihood	-0.02	0.06	0.72
Study	Oxybutynin	Failure	Masking of treatment status	Restricted maximum likelihood	0.22	0.15	0.24
Treatment	Oxybutynin	Failure	Daily dose	Restricted maximum likelihood	-0.01	0.02	0.81
Treatment	Oxybutynin	Failure	Weeks of treatment	Restricted maximum likelihood	0.01	0.02	0.63
Women	Oxybutynin	Failure	% of women	Restricted maximum likelihood	0	0	0.47
Women	Oxybutynin	Failure	Daily UI	Restricted maximum likelihood	0.13	0.07	0.19
Women	Oxybutynin	Failure	Inclusion of mixed UI	Restricted maximum likelihood	0.03	0.06	0.68

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Oxybutynin	Failure	Inclusion of prior failures	Restricted maximum likelihood	0.08	0.07	0.33
Women	Oxybutynin	Failure	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.11	0.07	0.22
Women	Oxybutynin	Failure	Rate in placebo group	Restricted maximum likelihood	-0.37	0.12	0.05
Study	Solifenacin	Adverse effects	Allocation concealment	Restricted maximum likelihood	-0.04	0.07	0.59
Study	Solifenacin	Adverse effects	Conflict of interest	Restricted maximum likelihood	0.04	0.09	0.64
Study	Solifenacin	Adverse effects	Country	Restricted maximum likelihood	0.03	0.12	0.8
Study	Solifenacin	Adverse effects	Intention to treat analysis	Restricted maximum likelihood	0.02	0.06	0.8
Treatment	Solifenacin	Adverse effects	Daily dose	Restricted maximum likelihood	0.02	0.01	0.08
Treatment	Solifenacin	Adverse effects	Weeks of treatment	Restricted maximum likelihood	0	0.01	0.8
Women	Solifenacin	Adverse effects	% of women	Restricted maximum likelihood	0	0.01	0.82
Women	Solifenacin	Adverse effects	Daily UI	Restricted maximum likelihood	-0.03	0.14	0.83
Women	Solifenacin	Adverse effects	Inclusion of mixed UI	Restricted maximum likelihood	-0.02	0.07	0.83
Women	Solifenacin	Adverse effects	Inclusion of prior failures	Restricted maximum likelihood	-0.08	0.14	0.59
Women	Solifenacin	Adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.08	0.14	0.59
Women	Solifenacin	Adverse effects	Rate in placebo group	Restricted maximum likelihood	-0.18	0.33	0.61
Study	Solifenacin	Blurred vision	Adequacy of randomization	Restricted maximum likelihood	-0.01	0	0.16
Study	Solifenacin	Blurred vision	Allocation concealment	Restricted maximum likelihood	0.01	0	0.2
Study	Solifenacin	Blurred vision	Conflict of interest	Restricted maximum likelihood	0	0.01	0.76

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Solifenacin	Blurred vision	Country	Restricted maximum likelihood	0	0	0.24
Study	Solifenacin	Blurred vision	Intention to treat analysis	Restricted maximum likelihood	-0.01	0.01	0.2
Study	Solifenacin	Blurred vision	Justification for sample size*	Restricted maximum likelihood	-0.02	0.01	0
Treatment	Solifenacin	Blurred vision	Daily dose	Restricted maximum likelihood	0	0	0.11
Treatment	Solifenacin	Blurred vision	Weeks of treatment	Restricted maximum likelihood	0	0	0.38
Women	Solifenacin	Blurred vision	% of women	Restricted maximum likelihood	0	0	0.27
Women	Solifenacin	Blurred vision	Daily UI	Restricted maximum likelihood	0.01	0.01	0.61
Women	Solifenacin	Blurred vision	Inclusion of minorities	Restricted maximum likelihood	-0.01	0.01	0.51
Women	Solifenacin	Blurred vision	Inclusion of mixed UI	Restricted maximum likelihood	0	0.01	0.49
Women	Solifenacin	Blurred vision	Inclusion of prior failures	Restricted maximum likelihood	0.01	0.01	0.44
Women	Solifenacin	Blurred vision	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.01	0.01	0.64
Women	Solifenacin	Blurred vision	Rate in placebo group	Restricted maximum likelihood	0.33	0.44	0.47
Study	Solifenacin	Constipation	Adequacy of randomization	Restricted maximum likelihood	0	0.02	0.94
Study	Solifenacin	Constipation	Allocation concealment	Restricted maximum likelihood	0	0.02	0.84
Study	Solifenacin	Constipation	Conflict of interest	Restricted maximum likelihood	0.01	0.02	0.73
Study	Solifenacin	Constipation	Country	Restricted maximum likelihood	-0.01	0.01	0.34
Study	Solifenacin	Constipation	Intention to treat analysis	Restricted maximum likelihood	-0.01	0.01	0.46
Study	Solifenacin	Constipation	Justification for sample size	Restricted maximum likelihood	0	0.02	0.95

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Solifenacin	Constipation	Daily dose*	Restricted maximum likelihood	0.01	0	0
Treatment	Solifenacin	Constipation	Weeks of treatment	Restricted maximum likelihood	0	0	0.78
Women	Solifenacin	Constipation	% of women	Restricted maximum likelihood	0	0	0.95
Women	Solifenacin	Constipation	Daily UI	Restricted maximum likelihood	0.01	0.03	0.78
Women	Solifenacin	Constipation	Inclusion of mixed UI	Restricted maximum likelihood	0.01	0.02	0.47
Women	Solifenacin	Constipation	Inclusion of prior failures	Restricted maximum likelihood	-0.01	0.03	0.85
Women	Solifenacin	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.01	0.04	0.77
Women	Solifenacin	Constipation	Inclusion of minorities	Restricted maximum likelihood	-0.02	0.02	0.35
Women	Solifenacin	Constipation	Rate in placebo group	Restricted maximum likelihood	0.12	0.56	0.83
Study	Solifenacin	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	0.01	0.03	0.84
Study	Solifenacin	Dry mouth	Allocation concealment	Restricted maximum likelihood	0	0.04	0.92
Study	Solifenacin	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.01	0.05	0.88
Study	Solifenacin	Dry mouth	Country	Restricted maximum likelihood	0	0.02	0.86
Study	Solifenacin	Dry mouth	Intention to treat analysis	Restricted maximum likelihood	0.01	0.03	0.87
Study	Solifenacin	Dry mouth	Justification for sample size	Restricted maximum likelihood	0.01	0.06	0.82
Treatment	Solifenacin	Dry mouth	Daily dose*	Restricted maximum likelihood	0.03	0	0
Treatment	Solifenacin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.01	0.01	0.35
Women	Solifenacin	Dry mouth	% of women	Restricted maximum likelihood	0	0	0.56

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Solifenacin	Dry mouth	Daily UI	Restricted maximum likelihood	0.03	0.07	0.65
Women	Solifenacin	Dry mouth	Inclusion of mixed UI	Restricted maximum likelihood	0.03	0.04	0.54
Women	Solifenacin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.01	0.07	0.93
Women	Solifenacin	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	0.01	0.06	0.87
Women	Solifenacin	Dry mouth	Rate in placebo group	Restricted maximum likelihood	-0.12	1.11	0.92
Study	Solifenacin	Treatment discontinuation due to adverse effects	Adequacy of randomization	Restricted maximum likelihood	0	0.01	0.58
Study	Solifenacin	Treatment discontinuation due to adverse effects	Allocation concealment	Restricted maximum likelihood	0.01	0.01	0.56
Study	Solifenacin	Treatment discontinuation due to adverse effects	Conflict of interest	Restricted maximum likelihood	0	0.01	0.92
Study	Solifenacin	Treatment discontinuation due to adverse effects	Country	Restricted maximum likelihood	0	0.01	0.57
Study	Solifenacin	Treatment discontinuation due to adverse effects	Intention to treat analysis	Restricted maximum likelihood	-0.01	0.01	0.3
Study	Solifenacin	Treatment discontinuation due to adverse effects	Justification for sample size	Restricted maximum likelihood	0.01	0.01	0.4
Treatment	Solifenacin	Treatment discontinuation due to adverse effects	Daily dose	Restricted maximum likelihood	0	0	0.11
Treatment	Solifenacin	Treatment discontinuation due to adverse effects	Weeks of treatment	Restricted maximum likelihood	0	0.01	0.76
Women	Solifenacin	Treatment discontinuation due to adverse effects	% of women	Restricted maximum likelihood	0	0	0.16

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Solifenacin	Treatment discontinuation due to adverse effects	Daily UI	Restricted maximum likelihood	-0.01	0.02	0.77
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of minorities	Restricted maximum likelihood	0	0.01	0.78
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of mixed UI	Restricted maximum likelihood	0	0.01	0.92
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of prior failures	Restricted maximum likelihood	-0.01	0.01	0.51
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.05	0.02	0.1
Women	Solifenacin	Treatment discontinuation due to adverse effects	Rate in placebo group	Restricted maximum likelihood	-0.03	0.58	0.96
Study	Tolterodine	Dry mouth	Adequate randomization	Restricted maximum likelihood	-0.01	0.02	0.46
Study	Tolterodine	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.02	0.03	0.5
Study	Tolterodine	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.06	0.04	0.14
Study	Tolterodine	Dry mouth	Country	Restricted maximum likelihood	0	0.02	0.9
Study	Tolterodine	Dry mouth	Intention to treat	Restricted maximum likelihood	0.04	0.02	0.07
Study	Tolterodine	Dry mouth	Justification of sample size	Restricted maximum likelihood	0	0.03	0.97
Treatment	Tolterodine	Dry mouth	Daily dose	Restricted maximum likelihood	0.01	0.01	0.52
Treatment	Tolterodine	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.01	0.01	0.06
Women	Tolterodine	Dry mouth	% of women	Restricted maximum likelihood	0	0	0.14
Women	Tolterodine	Dry mouth	Daily UI	Restricted maximum likelihood	-0.05	0.05	0.31

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.04	0.04	0.36
Women	Tolterodine	Dry mouth	Inclusion of mixed UI	Restricted maximum likelihood	0	0.03	0.87
Women	Tolterodine	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	0.01	0.03	0.65
Women	Tolterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.07	0.05	0.21
Women	Tolterodine	Dry mouth	Rate in placebo group	Restricted maximum likelihood	0.16	0.45	0.73
Study	Tolterodine	Failure	Adequate randomization	Restricted maximum likelihood	0.05	0.02	0.07
Study	Tolterodine	Failure	Allocation concealment	Restricted maximum likelihood	-0.04	0.03	0.22
Study	Tolterodine	Failure	Conflict of interest	Restricted maximum likelihood	-0.06	0.04	0.21
Study	Tolterodine	Failure	Country	Restricted maximum likelihood	-0.03	0.03	0.34
Study	Tolterodine	Failure	Intention to treat	Restricted maximum likelihood	0.01	0.04	0.87
Study	Tolterodine	Failure	Justification of sample size	Restricted maximum likelihood	0.03	0.05	0.58
Treatment	Tolterodine	Failure	Daily dose	Restricted maximum likelihood	0.02	0.05	0.75
Women	Tolterodine	Failure	% of women	Restricted maximum likelihood	0	0	0.46
Women	Tolterodine	Failure	Daily UI	Restricted maximum likelihood	-0.04	0.07	0.61
Women	Tolterodine	Failure	Inclusion of minorities	Restricted maximum likelihood	-0.01	0.07	0.9
Women	Tolterodine	Failure	Inclusion of mixed UI	Restricted maximum likelihood	0.08	0.06	0.26
Women	Tolterodine	Failure	Inclusion of prior failures	Restricted maximum likelihood	-0.08	0.06	0.22
Women	Tolterodine	Failure	Rate in placebo group*	Restricted maximum likelihood	-0.51	0.09	0

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Tolterodine	Improvement in UI	Adequate randomization	Restricted maximum likelihood	0	0.02	0.92
Study	Tolterodine	Improvement in UI	Allocation concealment	Restricted maximum likelihood	0.02	0.03	0.53
Study	Tolterodine	Improvement in UI	Conflict of interest	Restricted maximum likelihood	0.05	0.04	0.24
Study	Tolterodine	Improvement in UI	Country	Restricted maximum likelihood	0.01	0.03	0.81
Study	Tolterodine	Improvement in UI	Intention to treat	Restricted maximum likelihood	-0.04	0.03	0.28
Study	Tolterodine	Improvement in UI	Justification of sample size	Restricted maximum likelihood	-0.06	0.03	0.07
Treatment	Tolterodine	Improvement in UI	Daily dose	Restricted maximum likelihood	-0.05	0.03	0.18
Women	Tolterodine	Improvement in UI	% of women	Restricted maximum likelihood	0	0	0.15
Women	Tolterodine	Improvement in UI	Daily UI	Restricted maximum likelihood	-0.09	0.05	0.1
Women	Tolterodine	Improvement in UI	Inclusion of minorities	Restricted maximum likelihood	0.05	0.05	0.41
Women	Tolterodine	Improvement in UI	Inclusion of mixed UI*	Restricted maximum likelihood	-0.13	0.04	0.02
Women	Tolterodine	Improvement in UI	Inclusion of prior failures	Restricted maximum likelihood	-0.02	0.04	0.7
Women	Tolterodine	Improvement in UI	Rate in placebo group	Restricted maximum likelihood	0.1	0.2	0.62
Study	Tolterodine	Treatment discontinuation due to adverse effects	Adequate randomization	Restricted maximum likelihood	-0.006	0.00713	0.461
Study	Tolterodine	Treatment discontinuation due to adverse effects	Allocation concealment	Restricted maximum likelihood	0.008	0.008	0.365
Study	Tolterodine	Treatment discontinuation due to adverse effects	Conflict of interest	Restricted maximum likelihood	0.025	0.012	0.063
Study	Tolterodine	Treatment discontinuation due to adverse effects	Intention to treat	Restricted maximum likelihood	0.004	0.011	0.718

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Tolterodine	Treatment discontinuation due to adverse effects	Justification of sample size	Restricted maximum likelihood	-0.011	0.01	0.326
Treatment	Tolterodine	Treatment discontinuation due to adverse effects	Daily dose	Restricted maximum likelihood	-0.012	0.015	0.432
Women	Tolterodine	Treatment discontinuation due to adverse effects	Country	Restricted maximum likelihood	0.0034	0.006	0.58
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of prior failures	Restricted maximum likelihood	-0.003	0.021	0.872
Women	Tolterodine	Treatment discontinuation due to adverse effects	% of women	Restricted maximum likelihood	0.0000132	0.001	0.99
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of minorities	Restricted maximum likelihood	-0.004	0.021	0.854
Women	Tolterodine	Treatment discontinuation due to adverse effects	Rate in placebo group	Restricted maximum likelihood	-0.78	0.26	0.014
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.009	0.022	0.691
Women	Tolterodine	Treatment discontinuation due to adverse effects	Weeks of treatment	Restricted maximum likelihood	-0.0002	0.003	0.946
Study	Tolterodine	Headache	Adequate randomization	Restricted maximum likelihood	-0.003	0.007	0.659
Study	Tolterodine	Headache	Allocation concealment	Restricted maximum likelihood	0.0018	0.006	0.784
Study	Tolterodine	Headache	Conflict of interest	Restricted maximum likelihood	0.0083	0.012	0.498
Study	Tolterodine	Headache	Intention to treat	Restricted maximum likelihood	-0.0069	0.007	0.351
Study	Tolterodine	Headache	Justification of sample size	Restricted maximum likelihood	0.0021	0.006	0.729

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Tolterodine	Headache	Daily dose	Restricted maximum likelihood	-0.0012	0.011	0.914
Women	Tolterodine	Headache	Country	Restricted maximum likelihood	-0.0037	0.0047	0.445
Women	Tolterodine	Headache	Daily UI	Restricted maximum likelihood	0.01	0.014	0.492
Women	Tolterodine	Headache	Inclusion of prior failures	Restricted maximum likelihood	-0.017	0.01	0.079
Women	Tolterodine	Headache	% of women	Restricted maximum likelihood	-0.0003	0.001	0.606
Women	Tolterodine	Headache	Inclusion of minorities	Restricted maximum likelihood	-0.01	0.01	0.37
Women	Tolterodine	Headache	Rate in placebo group	Restricted maximum likelihood	-1.03	0.4	0.021
Women	Tolterodine	Headache	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.013	0.02	0.583
Women	Tolterodine	Headache	Weeks of treatment	Restricted maximum likelihood	0.0002	0.002	0.913
Study	Tolterodine	Constipation	Adequate randomization	Restricted maximum likelihood	0.003	0.003	0.402
Study	Tolterodine	Constipation	Allocation concealment	Restricted maximum likelihood	-0.001	0.003	0.841
Study	Tolterodine	Constipation	Conflict of interest	Restricted maximum likelihood	0.001	0.01	0.92
Study	Tolterodine	Constipation	Intention to treat	Restricted maximum likelihood	0.0001	0.01	0.98
Study	Tolterodine	Constipation	Justification of sample size	Restricted maximum likelihood	-0.001	0.004	0.745
Treatment	Tolterodine	Constipation	Daily dose	Restricted maximum likelihood	-0.0003	0.002	0.882
Women	Tolterodine	Constipation	Country	Restricted maximum likelihood	0.002	0.003	0.501
Women	Tolterodine	Constipation	Daily UI	Restricted maximum likelihood	-0.012	0.011	0.285
Women	Tolterodine	Constipation	Inclusion of prior failures	Restricted maximum likelihood	0.002	0.01	0.884

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Constipation	% of women	Restricted maximum likelihood	0.0001	0.0004	0.855
Women	Tolterodine	Constipation	Inclusion of minorities	Restricted maximum likelihood	-0.0004	0.01	0.956
Women	Tolterodine	Constipation	Rate in placebo group	Restricted maximum likelihood	-0.12	0.27	0.697
Women	Tolterodine	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.004	0.012	0.751
Women	Tolterodine	Constipation	Weeks of treatment	Restricted maximum likelihood	0.001	0.001	0.429
Study	Trospium	Dry mouth	Adequate randomization	Restricted maximum likelihood	-0.06	0.04	0.15
Study	Trospium	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.03	0.03	0.29
Study	Trospium	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.03	0.05	0.62
Study	Trospium	Dry mouth	Country	Restricted maximum likelihood	-0.01	0.03	0.77
Study	Trospium	Dry mouth	Intention to treat	Restricted maximum likelihood	-0.04	0.04	0.36
Study	Trospium	Dry mouth	Justification of sample size	Restricted maximum likelihood	-0.01	0.03	0.8
Treatment	Trospium	Dry mouth	Daily dose*	Restricted maximum likelihood	0	0	0.02
Treatment	Trospium	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.01	0.01	0.15
Women	Trospium	Dry mouth	% of women	Restricted maximum likelihood	0	0	0.12
Women	Trospium	Dry mouth	Daily UI	Restricted maximum likelihood	-0.13	0.07	0.15
Women	Trospium	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.13	0.07	0.15
Women	Trospium	Dry mouth	Inclusion of mixed UI	Restricted maximum likelihood	0.04	0.02	0.14
Women	Trospium	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.03	0.06	0.66

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Trospium	Dry mouth	Rate in placebo group*	Restricted maximum likelihood	3.28	0.85	0.02
Diversity factor	Drug	Outcome	Contributing variable	Estimate of between study variance	Coefficient (log RR)	Standard error	P values
Study	Darifenacin	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	0.40	0.30	0.236
Study	Darifenacin	Dry mouth	Intention to treat analyses	Restricted maximum likelihood	0.40	0.30	0.236
Treatment	Darifenacin	Dry mouth	Daily dose	Restricted maximum likelihood	0.00	0.03	0.884
Treatment	Darifenacin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	0.05	0.07	0.537
Women	Darifenacin	Dry mouth	% women	Restricted maximum likelihood	0.02	0.02	0.294
Women	Darifenacin	Dry mouth	Control rate	Restricted maximum likelihood	-18.41	9.46	0.093
Women	Darifenacin	Dry mouth	Country	Restricted maximum likelihood	0.01	0.17	0.944
Women	Darifenacin	Dry mouth	Daily UI	Restricted maximum likelihood	0.80	0.60	0.236
Women	Darifenacin	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.80	0.60	0.236
Women	Darifenacin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	0.17	0.20	0.438
Women	Darifenacin	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.15	0.33	0.663
Study	Darifenacin	Treatment discontinuation due to adverse effects	Adequacy of randomization	Restricted maximum likelihood	-0.11	0.29	0.726
Study	Darifenacin	Treatment discontinuation due to adverse effects	Conflict of interest	Restricted maximum likelihood	-0.69	0.57	0.269
Study	Darifenacin	Treatment discontinuation due to adverse effects	Intention to treat analyses	Restricted maximum likelihood	0.34	0.29	0.269
Study	Darifenacin	Treatment discontinuation due to adverse effects	Justification of sample size	Restricted maximum likelihood	-0.21	0.59	0.726

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Darifenacin	Treatment discontinuation due to adverse effects	Daily dose	Restricted maximum likelihood	0.06	0.03	0.064
Women	Darifenacin	Treatment discontinuation due to adverse effects	% women	Restricted maximum likelihood	0.10	0.06	0.151
Women	Darifenacin	Treatment discontinuation due to adverse effects	Control rate	Restricted maximum likelihood	-11.02	6.85	0.142
Women	Darifenacin	Treatment discontinuation due to adverse effects	Country	Restricted maximum likelihood	-0.27	0.14	0.096
Women	Darifenacin	Treatment discontinuation due to adverse effects	Inclusion of minorities	Restricted maximum likelihood	0.21	0.59	0.726
Women	Darifenacin	Treatment discontinuation due to adverse effects	Inclusion of prior failures	Restricted maximum likelihood	0.25	0.33	0.462
Women	Darifenacin	Treatment discontinuation due to adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.57	0.48	0.278
Study	Fesoterodine	Constipation	Adequacy of randomization	Restricted maximum likelihood	0.00	0.23	0.993
Study	Fesoterodine	Constipation	Allocation concealment	Restricted maximum likelihood	-0.09	0.27	0.743
Study	Fesoterodine	Constipation	Conflict of interest	Restricted maximum likelihood	-0.16	0.54	0.77
Study	Fesoterodine	Constipation	Intention to treat analyses	Restricted maximum likelihood	0.62	0.53	0.273
Study	Fesoterodine	Constipation	Justification of sample size	Restricted maximum likelihood	0.17	0.31	0.601
Treatment	Fesoterodine	Constipation	Daily dose	Restricted maximum likelihood	0.02	0.12	0.853
Women	Fesoterodine	Constipation	% women	Restricted maximum likelihood	-0.06	0.03	0.125
Women	Fesoterodine	Constipation	Control rate	Restricted maximum likelihood	-21.40	21.02	0.338

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Fesoterodine	Constipation	Country	Restricted maximum likelihood	0.15	0.28	0.613
Women	Fesoterodine	Constipation	Inclusion of minorities	Restricted maximum likelihood	-0.19	0.55	0.743
Women	Fesoterodine	Constipation	Inclusion of prior failures	Restricted maximum likelihood	-0.05	0.54	0.925
Women	Fesoterodine	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.03	0.54	0.955
Study	Fesoterodine	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	0.03	0.08	0.748
Study	Fesoterodine	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.01	0.10	0.941
Study	Fesoterodine	Dry mouth	Conflict of interest	Restricted maximum likelihood	0.05	0.20	0.825
Study	Fesoterodine	Dry mouth	Intention to treat analyses	Restricted maximum likelihood	0.22	0.19	0.276
Study	Fesoterodine	Dry mouth	Justification of sample size	Restricted maximum likelihood	0.08	0.11	0.472
Treatment	Fesoterodine	Dry mouth	Daily dose	Restricted maximum likelihood	0.05	0.04	0.247
Women	Fesoterodine	Dry mouth	% women	Restricted maximum likelihood	-0.01	0.01	0.422
Women	Fesoterodine	Dry mouth	Control rate	Restricted maximum likelihood	-13.35	6.11	0.061
Women	Fesoterodine	Dry mouth	Country	Restricted maximum likelihood	-0.04	0.10	0.711
Women	Fesoterodine	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.02	0.20	0.941
Women	Fesoterodine	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	0.05	0.20	0.82
Women	Fesoterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.10	0.19	0.61
Study	Fesoterodine	Headache	Adequacy of randomization	Restricted maximum likelihood	0.00	0.11	0.975
Study	Fesoterodine	Headache	Allocation concealment	Restricted maximum likelihood	0.05	0.11	0.656

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Fesoterodine	Headache	Conflict of interest	Restricted maximum likelihood	0.11	0.25	0.657
Study	Fesoterodine	Headache	Intention to treat analyses	Restricted maximum likelihood	0.55	0.28	0.092
Study	Fesoterodine	Headache	Justification of sample size	Restricted maximum likelihood	0.32	0.17	0.094
Treatment	Fesoterodine	Headache	Daily dose	Restricted maximum likelihood	-0.03	0.04	0.447
Women	Fesoterodine	Headache	% women	Restricted maximum likelihood	-0.04	0.02	0.145
Women	Fesoterodine	Headache	Control rate	Restricted maximum likelihood	-1.26	1.81	0.511
Women	Fesoterodine	Headache	Country	Restricted maximum likelihood	-0.28	0.13	0.059
Women	Fesoterodine	Headache	Inclusion of minorities	Restricted maximum likelihood	0.11	0.23	0.656
Women	Fesoterodine	Headache	Inclusion of prior failures	Restricted maximum likelihood	0.03	0.25	0.895
Women	Fesoterodine	Headache	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.15	0.24	0.535
Study	Fesoterodine	Nausea	Adequacy of randomization	Restricted maximum likelihood	0.27	0.23	0.285
Study	Fesoterodine	Nausea	Allocation concealment	Restricted maximum likelihood	0.27	0.23	0.285
Study	Fesoterodine	Nausea	Conflict of interest	Restricted maximum likelihood	1.32	0.91	0.188
Study	Fesoterodine	Nausea	Intention to treat analyses	Restricted maximum likelihood	-0.26	0.47	0.608
Study	Fesoterodine	Nausea	Justification of sample size	Restricted maximum likelihood	-0.54	0.47	0.285
Treatment	Fesoterodine	Nausea	Daily dose	Restricted maximum likelihood	0.04	0.08	0.61
Women	Fesoterodine	Nausea	% women	Restricted maximum likelihood	0.02	0.06	0.733
Women	Fesoterodine	Nausea	Control rate	Restricted maximum likelihood	-10.13	8.69	0.282

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Fesoterodine	Nausea	Country	Restricted maximum likelihood	0.31	0.44	0.51
Women	Fesoterodine	Nausea	Inclusion of minorities	Restricted maximum likelihood	0.54	0.47	0.285
Women	Fesoterodine	Nausea	Inclusion of prior failures	Restricted maximum likelihood	0.54	0.47	0.285
Women	Fesoterodine	Nausea	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.54	0.47	0.285
Study	Oxybutynin	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	0.11	0.23	0.65
Study	Oxybutynin	Dry mouth	Allocation concealment	Restricted maximum likelihood	0.09	0.27	0.755
Study	Oxybutynin	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.59	0.63	0.385
Study	Oxybutynin	Dry mouth	Intention to treat analyses	Restricted maximum likelihood	0.29	0.20	0.198
Study	Oxybutynin	Dry mouth	Justification of sample size	Restricted maximum likelihood	0.11	0.33	0.744
Treatment	Oxybutynin	Dry mouth	Daily dose	Restricted maximum likelihood	0.05	0.04	0.198
Treatment	Oxybutynin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	0.02	0.06	0.708
Women	Oxybutynin	Dry mouth	% women	Restricted maximum likelihood	-0.03	0.02	0.145
Women	Oxybutynin	Dry mouth	Control rate	Restricted maximum likelihood	-1.16	0.72	0.151
Women	Oxybutynin	Dry mouth	Country	Restricted maximum likelihood	0.01	0.20	0.958
Women	Oxybutynin	Dry mouth	Daily UI	Restricted maximum likelihood	0.31	0.46	0.526
Women	Oxybutynin	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.59	0.53	0.309
Women	Oxybutynin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.15	0.44	0.744
Women	Oxybutynin	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.16	0.53	0.768

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Oxybutynin	Improvement in UI	Adequacy of randomization	Restricted maximum likelihood	-0.06	0.11	0.593
Study	Oxybutynin	Improvement in UI	Allocation concealment	Restricted maximum likelihood	0.08	0.17	0.648
Study	Oxybutynin	Improvement in UI	Intention to treat analyses	Restricted maximum likelihood	-0.04	0.14	0.795
Study	Oxybutynin	Improvement in UI	Justification of sample size	Restricted maximum likelihood	0.00	0.13	0.988
Treatment	Oxybutynin	Improvement in UI	Daily dose	Restricted maximum likelihood	-0.04	0.03	0.21
Treatment	Oxybutynin	Improvement in UI	Weeks of treatment	Restricted maximum likelihood	0.00	0.04	0.903
Women	Oxybutynin	Improvement in UI	% women	Restricted maximum likelihood	0.00	0.01	0.833
Women	Oxybutynin	Improvement in UI	Control rate	Restricted maximum likelihood	-1.33	0.59	0.058
Women	Oxybutynin	Improvement in UI	Country	Restricted maximum likelihood	-0.14	0.07	0.074
Women	Oxybutynin	Improvement in UI	Daily UI	Restricted maximum likelihood	0.10	0.24	0.688
Women	Oxybutynin	Improvement in UI	Inclusion of prior failures	Restricted maximum likelihood	0.11	0.24	0.653
Women	Oxybutynin	Improvement in UI	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.18	0.24	0.471
Study	Solifenacin	Blurred vision	Adequacy of randomization	Restricted maximum likelihood	-0.12	0.12	0.323
Study	Solifenacin	Blurred vision	Allocation concealment	Restricted maximum likelihood	0.45	0.21	0.048
Study	Solifenacin	Blurred vision	Conflict of interest	Restricted maximum likelihood	0.04	0.23	0.853
Study	Solifenacin	Blurred vision	Intention to treat analyses	Restricted maximum likelihood	-0.26	0.19	0.198
Study	Solifenacin	Blurred vision	Justification of sample size	Restricted maximum likelihood	-0.41	0.24	0.105
Treatment	Solifenacin	Blurred vision	Daily dose	Restricted maximum likelihood	0.06	0.04	0.143

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Solifenacin	Blurred vision	Weeks of treatment	Restricted maximum likelihood	0.01	0.06	0.818
Women	Solifenacin	Blurred vision	% women	Restricted maximum likelihood	0.00	0.02	0.96
Women	Solifenacin	Blurred vision	Control rate	Restricted maximum likelihood	-9.74	12.93	0.464
Women	Solifenacin	Blurred vision	Country	Restricted maximum likelihood	-0.06	0.13	0.631
Women	Solifenacin	Blurred vision	Daily UI	Restricted maximum likelihood	0.10	0.45	0.823
Women	Solifenacin	Blurred vision	Inclusion of minorities	Restricted maximum likelihood	-0.15	0.27	0.576
Women	Solifenacin	Blurred vision	Inclusion of prior failures	Restricted maximum likelihood	0.12	0.24	0.637
Women	Solifenacin	Blurred vision	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-1.20	1.51	0.44
Study	Solifenacin	Constipation	Adequacy of randomization	Restricted maximum likelihood	-0.01	0.18	0.948
Study	Solifenacin	Constipation	Allocation concealment	Restricted maximum likelihood	-0.03	0.21	0.904
Study	Solifenacin	Constipation	Conflict of interest	Restricted maximum likelihood	-0.15	0.24	0.551
Study	Solifenacin	Constipation	Intention to treat analyses	Restricted maximum likelihood	0.05	0.26	0.855
Study	Solifenacin	Constipation	Justification of sample size	Restricted maximum likelihood	0.06	0.31	0.854
Treatment	Solifenacin	Constipation	Daily dose	Restricted maximum likelihood	0.14	0.05	0.012
Treatment	Solifenacin	Constipation	Weeks of treatment	Restricted maximum likelihood	-0.08	0.09	0.419
Women	Solifenacin	Constipation	% women	Restricted maximum likelihood	-0.01	0.02	0.615
Women	Solifenacin	Constipation	Control rate	Restricted maximum likelihood	-11.07	5.86	0.086
Women	Solifenacin	Constipation	Country	Restricted maximum likelihood	-0.09	0.14	0.511

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Solifenacin	Constipation	Daily UI	Restricted maximum likelihood	0.31	0.36	0.41
Women	Solifenacin	Constipation	Inclusion of minorities	Restricted maximum likelihood	-0.28	0.32	0.393
Women	Solifenacin	Constipation	Inclusion of prior failures	Restricted maximum likelihood	-0.02	0.34	0.949
Women	Solifenacin	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.21	0.59	0.721
Study	Solifenacin	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	0.02	0.18	0.926
Study	Solifenacin	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.09	0.25	0.708
Study	Solifenacin	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.24	0.33	0.478
Study	Solifenacin	Dry mouth	Intention to treat analyses	Restricted maximum likelihood	0.26	0.25	0.334
Study	Solifenacin	Dry mouth	Justification of sample size	Restricted maximum likelihood	0.07	0.32	0.836
Treatment	Solifenacin	Dry mouth	Daily dose	Restricted maximum likelihood	0.17	0.03	0
Treatment	Solifenacin	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.10	0.09	0.284
Women	Solifenacin	Dry mouth	% women	Restricted maximum likelihood	-0.02	0.02	0.367
Women	Solifenacin	Dry mouth	Control rate	Restricted maximum likelihood	-11.86	7.42	0.141
Women	Solifenacin	Dry mouth	Country	Restricted maximum likelihood	0.04	0.15	0.79
Women	Solifenacin	Dry mouth	Daily UI	Restricted maximum likelihood	0.18	0.38	0.657
Women	Solifenacin	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.01	0.37	0.969
Women	Solifenacin	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	-0.06	0.37	0.881
Study	Solifenacin	Treatment discontinuation	Allocation concealment	Restricted maximum likelihood	0.19	0.09	0.09

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Solifenacin	Treatment discontinuation	Conflict of interest	Restricted maximum likelihood	-0.15	0.11	0.241
Study	Solifenacin	Treatment discontinuation	Intention to treat analyses	Restricted maximum likelihood	-0.18	0.11	0.148
Treatment	Solifenacin	Treatment discontinuation	Daily dose	Restricted maximum likelihood	0.02	0.05	0.653
Treatment	Solifenacin	Treatment discontinuation	Weeks of treatment	Restricted maximum likelihood	-0.02	0.04	0.627
Women	Solifenacin	Treatment discontinuation	% women	Restricted maximum likelihood	0.00	0.01	0.736
Women	Solifenacin	Treatment discontinuation	Control rate	Restricted maximum likelihood	3.61	2.31	0.162
Women	Solifenacin	Treatment discontinuation	Country	Restricted maximum likelihood	-0.01	0.09	0.905
Women	Solifenacin	Treatment discontinuation	Daily UI	Restricted maximum likelihood	0.62	0.43	0.193
Women	Solifenacin	Treatment discontinuation	Inclusion of minorities	Restricted maximum likelihood	-0.20	0.24	0.444
Women	Solifenacin	Treatment discontinuation	Inclusion of prior failures	Restricted maximum likelihood	0.08	0.22	0.71
Women	Solifenacin	Treatment discontinuation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.37	0.19	0.09
Study	Solifenacin	Treatment discontinuation due to adverse effects	Adequacy of randomization	Restricted maximum likelihood	0.08	0.18	0.676
Study	Solifenacin	Treatment discontinuation due to adverse effects	Allocation concealment	Restricted maximum likelihood	0.06	0.19	0.776
Study	Solifenacin	Treatment discontinuation due to adverse effects	Conflict of interest	Restricted maximum likelihood	0.03	0.19	0.862
Study	Solifenacin	Treatment discontinuation due to adverse effects	Intention to treat analyses	Restricted maximum likelihood	-0.27	0.26	0.328
Study	Solifenacin	Treatment discontinuation due to adverse effects	Justification of sample size	Restricted maximum likelihood	0.29	0.23	0.233

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Solifenacin	Treatment discontinuation due to adverse effects	Daily dose	Restricted maximum likelihood	0.08	0.05	0.134
Treatment	Solifenacin	Treatment discontinuation due to adverse effects	Weeks of treatment	Restricted maximum likelihood	-0.01	0.16	0.973
Women	Solifenacin	Treatment discontinuation due to adverse effects	% women	Restricted maximum likelihood	0.04	0.02	0.048
Women	Solifenacin	Treatment discontinuation due to adverse effects	Control rate	Restricted maximum likelihood	-7.58	12.27	0.552
Women	Solifenacin	Treatment discontinuation due to adverse effects	Country	Restricted maximum likelihood	0.11	0.13	0.397
Women	Solifenacin	Treatment discontinuation due to adverse effects	Daily UI	Restricted maximum likelihood	-0.05	0.42	0.912
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of minorities	Restricted maximum likelihood	-0.04	0.27	0.894
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of prior failures	Restricted maximum likelihood	-0.26	0.24	0.315
Women	Solifenacin	Treatment discontinuation due to adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.45	0.34	0.214
Study	Tolterodine	Adverse effects	Adequacy of randomization	Restricted maximum likelihood	-0.13	0.05	0.014
Study	Tolterodine	Adverse effects	Adequacy of randomization	Empirical Bayes	-0.13	0.05	0.014
Study	Tolterodine	Adverse effects	Adequacy of randomization	Method of moments	-0.13	0.05	0.014
Study	Tolterodine	Adverse effects	Allocation concealment	Restricted maximum likelihood	0.04	0.05	0.385
Study	Tolterodine	Adverse effects	Allocation concealment	Empirical Bayes	0.03	0.07	0.668
Study	Tolterodine	Adverse effects	Allocation concealment	Method of moments	0.04	0.06	0.567
Study	Tolterodine	Adverse effects	Conflict of interest	Restricted maximum likelihood	0.01	0.10	0.952
Study	Tolterodine	Adverse effects	Conflict of interest	Empirical Bayes	-0.01	0.13	0.939

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Study	Tolterodine	Adverse effects	Conflict of interest	Method of moments	0.00	0.11	0.987
Study	Tolterodine	Adverse effects	Intention to treat analyses	Restricted maximum likelihood	0.02	0.05	0.683
Study	Tolterodine	Adverse effects	Intention to treat analyses	Empirical Bayes	0.04	0.06	0.589
Study	Tolterodine	Adverse effects	Intention to treat analyses	Method of moments	0.03	0.06	0.634
Study	Tolterodine	Adverse effects	Justification of sample size	Restricted maximum likelihood	-0.08	0.06	0.186
Study	Tolterodine	Adverse effects	Justification of sample size	Empirical Bayes	-0.05	0.08	0.548
Study	Tolterodine	Adverse effects	Justification of sample size	Method of moments	-0.06	0.07	0.356
Treatment	Tolterodine	Adverse effects	Daily dose	Restricted maximum likelihood	0.12	0.07	0.09
Treatment	Tolterodine	Adverse effects	Daily dose	Empirical Bayes	0.12	0.06	0.071
Treatment	Tolterodine	Adverse effects	Daily dose	Method of moments	0.12	0.06	0.077
Treatment	Tolterodine	Adverse effects	Weeks of treatment	Restricted maximum likelihood	-0.01	0.01	0.716
Treatment	Tolterodine	Adverse effects	Weeks of treatment	Empirical Bayes	-0.01	0.02	0.743
Treatment	Tolterodine	Adverse effects	Weeks of treatment	Method of moments	-0.01	0.01	0.736
Women	Tolterodine	Adverse effects	% women	Restricted maximum likelihood	0.00	0.00	0.59
Women	Tolterodine	Adverse effects	% women	Empirical Bayes	0.00	0.01	0.535
Women	Tolterodine	Adverse effects	% women	Method of moments	0.00	0.01	0.564
Women	Tolterodine	Adverse effects	Control rate	Restricted maximum likelihood	-0.42	0.17	0.024
Women	Tolterodine	Adverse effects	Control rate	Empirical Bayes	-0.44	0.17	0.024
Women	Tolterodine	Adverse effects	Control rate	Method of moments	-0.44	0.17	0.024
Women	Tolterodine	Adverse effects	Country	Restricted maximum likelihood	0.02	0.05	0.719
Women	Tolterodine	Adverse effects	Country	Empirical Bayes	0.02	0.06	0.756
Women	Tolterodine	Adverse effects	Country	Method of moments	0.02	0.05	0.725
Women	Tolterodine	Adverse effects	Daily UI	Restricted maximum likelihood	-0.64	0.35	0.093
Women	Tolterodine	Adverse effects	Daily UI	Empirical Bayes	-0.63	0.33	0.075
Women	Tolterodine	Adverse effects	Daily UI	Method of moments	-0.63	0.33	0.08
Women	Tolterodine	Adverse effects	Inclusion of minorities	Restricted maximum likelihood	-0.03	0.09	0.781
Women	Tolterodine	Adverse effects	Inclusion of minorities	Empirical Bayes	-0.02	0.12	0.85
Women	Tolterodine	Adverse effects	Inclusion of minorities	Method of moments	-0.03	0.11	0.807

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Adverse effects	Inclusion of prior failures	Restricted maximum likelihood	0.03	0.07	0.673
Women	Tolterodine	Adverse effects	Inclusion of prior failures	Empirical Bayes	0.04	0.09	0.65
Women	Tolterodine	Adverse effects	Inclusion of prior failures	Method of moments	0.04	0.08	0.662
Women	Tolterodine	Adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.08	0.08	0.305
Women	Tolterodine	Adverse effects	Inclusion of women with surgical risk factors for UI	Empirical Bayes	-0.09	0.11	0.453
Women	Tolterodine	Adverse effects	Inclusion of women with surgical risk factors for UI	Method of moments	-0.09	0.10	0.392
Study	Tolterodine	Constipation	Adequacy of randomization	Restricted maximum likelihood	0.05	0.12	0.672
Study	Tolterodine	Constipation	Adequacy of randomization	Method of moments	0.05	0.12	0.672
Study	Tolterodine	Constipation	Allocation concealment	Restricted maximum likelihood	0.08	0.15	0.607
Study	Tolterodine	Constipation	Allocation concealment	Method of moments	0.08	0.15	0.607
Study	Tolterodine	Constipation	Conflict of interest	Restricted maximum likelihood	-0.03	0.28	0.923
Study	Tolterodine	Constipation	Conflict of interest	Method of moments	-0.03	0.28	0.923
Study	Tolterodine	Constipation	Intention to treat analyses	Restricted maximum likelihood	0.03	0.17	0.863
Study	Tolterodine	Constipation	Intention to treat analyses	Method of moments	0.03	0.17	0.863
Study	Tolterodine	Constipation	Justification of sample size	Restricted maximum likelihood	0.00	0.12	0.972
Study	Tolterodine	Constipation	Justification of sample size	Method of moments	0.00	0.12	0.972
Treatment	Tolterodine	Constipation	Daily dose	Restricted maximum likelihood	0.01	0.09	0.925
Treatment	Tolterodine	Constipation	Daily dose	Method of moments	0.01	0.09	0.925
Treatment	Tolterodine	Constipation	Weeks of treatment	Restricted maximum likelihood	0.01	0.04	0.811
Treatment	Tolterodine	Constipation	Weeks of treatment	Method of moments	0.01	0.04	0.811
Women	Tolterodine	Constipation	% women	Restricted maximum likelihood	-0.01	0.02	0.529
Women	Tolterodine	Constipation	% women	Restricted maximum likelihood	-0.01	0.02	0.529
Women	Tolterodine	Constipation	Control rate	Restricted maximum likelihood	-13.18	9.62	0.187

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Constipation	Control rate	Method of moments	-13.18	9.62	0.187
Women	Tolterodine	Constipation	Country	Restricted maximum likelihood	0.07	0.10	0.471
Women	Tolterodine	Constipation	Country	Method of moments	0.07	0.10	0.471
Women	Tolterodine	Constipation	Daily UI	Restricted maximum likelihood	-0.07	0.24	0.779
Women	Tolterodine	Constipation	Daily UI	Method of moments	-0.07	0.24	0.779
Women	Tolterodine	Constipation	Inclusion of minorities	Restricted maximum likelihood	0.05	0.26	0.857
Women	Tolterodine	Constipation	Inclusion of minorities	Method of moments	0.05	0.26	0.857
Women	Tolterodine	Constipation	Inclusion of prior failures	Restricted maximum likelihood	0.09	0.24	0.724
Women	Tolterodine	Constipation	Inclusion of prior failures	Method of moments	0.09	0.24	0.724
Women	Tolterodine	Constipation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.35	0.62	0.585
Women	Tolterodine	Constipation	Inclusion of women with surgical risk factors for UI	Method of moments	-0.35	0.62	0.585
Study	Tolterodine	Dry mouth	Adequacy of randomization	Restricted maximum likelihood	-0.08	0.09	0.386
Study	Tolterodine	Dry mouth	Adequacy of randomization	Empirical Bayes	-0.12	0.11	0.294
Study	Tolterodine	Dry mouth	Adequacy of randomization	Method of moments	-0.11	0.10	0.316
Study	Tolterodine	Dry mouth	Allocation concealment	Restricted maximum likelihood	-0.01	0.11	0.898
Study	Tolterodine	Dry mouth	Allocation concealment	Empirical Bayes	-0.02	0.15	0.892
Study	Tolterodine	Dry mouth	Allocation concealment	Method of moments	-0.02	0.13	0.903
Study	Tolterodine	Dry mouth	Conflict of interest	Restricted maximum likelihood	-0.26	0.17	0.14
Study	Tolterodine	Dry mouth	Conflict of interest	Empirical Bayes	-0.26	0.20	0.213
Study	Tolterodine	Dry mouth	Conflict of interest	Method of moments	-0.26	0.18	0.173
Study	Tolterodine	Dry mouth	Intention to treat analyses	Restricted maximum likelihood	0.10	0.11	0.382
Study	Tolterodine	Dry mouth	Intention to treat analyses	Empirical Bayes	0.11	0.14	0.417
Study	Tolterodine	Dry mouth	Intention to treat analyses	Method of moments	0.11	0.13	0.411
Study	Tolterodine	Dry mouth	Justification of sample size	Restricted maximum likelihood	-0.07	0.10	0.485
Study	Tolterodine	Dry mouth	Justification of sample size	Empirical Bayes	-0.06	0.14	0.682
Study	Tolterodine	Dry mouth	Justification of sample size	Method of moments	-0.06	0.12	0.612

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Treatment	Tolterodine	Dry mouth	Daily dose	Restricted maximum likelihood	0.08	0.05	0.139
Treatment	Tolterodine	Dry mouth	Daily dose	Empirical Bayes	0.09	0.06	0.139
Treatment	Tolterodine	Dry mouth	Daily dose	Method of moments	0.08	0.05	0.138
Treatment	Tolterodine	Dry mouth	Weeks of treatment	Restricted maximum likelihood	-0.02	0.03	0.588
Treatment	Tolterodine	Dry mouth	Weeks of treatment	Empirical Bayes	-0.02	0.03	0.651
Treatment	Tolterodine	Dry mouth	Weeks of treatment	Method of moments	-0.02	0.03	0.605
Women	Tolterodine	Dry mouth	% women	Restricted maximum likelihood	-0.01	0.01	0.152
Women	Tolterodine	Dry mouth	% women	Empirical Bayes	-0.02	0.01	0.142
Women	Tolterodine	Dry mouth	% women	Method of moments	-0.02	0.01	0.143
Women	Tolterodine	Dry mouth	Control rate	Restricted maximum likelihood	-2.89	1.89	0.147
Women	Tolterodine	Dry mouth	Control rate	Empirical Bayes	-3.26	2.03	0.129
Women	Tolterodine	Dry mouth	Control rate	Method of moments	-3.11	1.98	0.136
Women	Tolterodine	Dry mouth	Country	Restricted maximum likelihood	-0.07	0.07	0.378
Women	Tolterodine	Dry mouth	Country	Empirical Bayes	-0.09	0.09	0.332
Women	Tolterodine	Dry mouth	Country	Method of moments	-0.08	0.08	0.341
Women	Tolterodine	Dry mouth	Daily UI	Restricted maximum likelihood	-0.23	0.20	0.267
Women	Tolterodine	Dry mouth	Daily UI	Empirical Bayes	-0.27	0.28	0.36
Women	Tolterodine	Dry mouth	Daily UI	Method of moments	-0.25	0.25	0.326
Women	Tolterodine	Dry mouth	Inclusion of minorities	Restricted maximum likelihood	-0.16	0.17	0.355
Women	Tolterodine	Dry mouth	Inclusion of minorities	Empirical Bayes	-0.15	0.22	0.497
Women	Tolterodine	Dry mouth	Inclusion of minorities	Method of moments	-0.16	0.20	0.436
Women	Tolterodine	Dry mouth	Inclusion of prior failures	Restricted maximum likelihood	0.20	0.16	0.242
Women	Tolterodine	Dry mouth	Inclusion of prior failures	Empirical Bayes	0.18	0.21	0.399
Women	Tolterodine	Dry mouth	Inclusion of prior failures	Method of moments	0.19	0.19	0.318
Women	Tolterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.00	0.21	0.994
Women	Tolterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Empirical Bayes	0.00	0.27	0.992

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Dry mouth	Inclusion of women with surgical risk factors for UI	Method of moments	0.00	0.24	0.996
Study	Tolterodine	Headache	Adequacy of randomization	Restricted maximum likelihood	-0.13	0.15	0.405
Study	Tolterodine	Headache	Adequacy of randomization	Empirical Bayes	-0.13	0.15	0.405
Study	Tolterodine	Headache	Adequacy of randomization	Method of moments	-0.13	0.15	0.405
Study	Tolterodine	Headache	Allocation concealment	Restricted maximum likelihood	0.11	0.13	0.435
Study	Tolterodine	Headache	Allocation concealment	Empirical Bayes	0.11	0.13	0.435
Study	Tolterodine	Headache	Allocation concealment	Method of moments	0.11	0.13	0.435
Study	Tolterodine	Headache	Conflict of interest	Restricted maximum likelihood	0.03	0.26	0.918
Study	Tolterodine	Headache	Conflict of interest	Empirical Bayes	0.03	0.26	0.918
Study	Tolterodine	Headache	Conflict of interest	Method of moments	0.03	0.26	0.918
Study	Tolterodine	Headache	Intention to treat analyses	Restricted maximum likelihood	-0.02	0.16	0.925
Study	Tolterodine	Headache	Intention to treat analyses	Empirical Bayes	-0.02	0.16	0.925
Study	Tolterodine	Headache	Intention to treat analyses	Method of moments	-0.02	0.16	0.925
Study	Tolterodine	Headache	Justification of sample size	Restricted maximum likelihood	0.04	0.13	0.788
Study	Tolterodine	Headache	Justification of sample size	Empirical Bayes	0.04	0.13	0.788
Study	Tolterodine	Headache	Justification of sample size	Method of moments	0.04	0.13	0.788
Treatment	Tolterodine	Headache	Daily dose	Restricted maximum likelihood	-0.13	0.28	0.638
Treatment	Tolterodine	Headache	Daily dose	Empirical Bayes	-0.13	0.28	0.638
Treatment	Tolterodine	Headache	Daily dose	Method of moments	-0.13	0.28	0.638
Treatment	Tolterodine	Headache	Weeks of treatment	Restricted maximum likelihood	-0.03	0.05	0.483
Treatment	Tolterodine	Headache	Weeks of treatment	Empirical Bayes	-0.03	0.05	0.483
Treatment	Tolterodine	Headache	Weeks of treatment	Method of moments	-0.03	0.05	0.483
Women	Tolterodine	Headache	% women	Restricted maximum likelihood	-0.01	0.01	0.348
Women	Tolterodine	Headache	% women	Empirical Bayes	-0.01	0.01	0.348
Women	Tolterodine	Headache	% women	Method of moments	-0.01	0.01	0.348
Women	Tolterodine	Headache	Control rate	Restricted maximum likelihood	-24.03	12.96	0.087

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Headache	Country	Restricted maximum likelihood	-0.10	0.12	0.418
Women	Tolterodine	Headache	Country	Empirical Bayes	-0.10	0.12	0.418
Women	Tolterodine	Headache	Country	Method of moments	-0.10	0.12	0.418
Women	Tolterodine	Headache	Daily UI	Restricted maximum likelihood	0.18	0.26	0.497
Women	Tolterodine	Headache	Daily UI	Empirical Bayes	0.18	0.26	0.497
Women	Tolterodine	Headache	Daily UI	Method of moments	0.18	0.26	0.497
Women	Tolterodine	Headache	Inclusion of minorities	Restricted maximum likelihood	-0.05	0.25	0.842
Women	Tolterodine	Headache	Inclusion of minorities	Empirical Bayes	-0.05	0.25	0.842
Women	Tolterodine	Headache	Inclusion of minorities	Method of moments	-0.05	0.25	0.842
Women	Tolterodine	Headache	Inclusion of prior failures	Restricted maximum likelihood	-0.20	0.30	0.516
Women	Tolterodine	Headache	Inclusion of prior failures	Empirical Bayes	-0.20	0.30	0.516
Women	Tolterodine	Headache	Inclusion of prior failures	Method of moments	-0.20	0.30	0.516
Women	Tolterodine	Headache	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	0.25	0.39	0.54
Women	Tolterodine	Headache	Inclusion of women with surgical risk factors for UI	Empirical Bayes	0.25	0.39	0.54
Women	Tolterodine	Headache	Inclusion of women with surgical risk factors for UI	Method of moments	0.25	0.39	0.54
Study	Tolterodine	Treatment discontinuation	Adequacy of randomization	Restricted maximum likelihood	-0.02	0.38	0.965
Study	Tolterodine	Treatment discontinuation	Allocation concealment	Restricted maximum likelihood	0.08	0.12	0.533
Study	Tolterodine	Treatment discontinuation	Conflict of interest	Restricted maximum likelihood	0.23	0.22	0.326
Study	Tolterodine	Treatment discontinuation	Intention to treat analyses	Restricted maximum likelihood	-0.19	0.19	0.335
Study	Tolterodine	Treatment discontinuation	Justification of sample size	Restricted maximum likelihood	-0.04	0.13	0.749
Treatment	Tolterodine	Treatment discontinuation	Daily dose	Restricted maximum likelihood	-0.01	0.05	0.875
Treatment	Tolterodine	Treatment discontinuation	Weeks of treatment	Restricted maximum likelihood	-0.01	0.06	0.829

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Treatment discontinuation	% women	Restricted maximum likelihood	0.01	0.01	0.6
Women	Tolterodine	Treatment discontinuation	Control rate	Restricted maximum likelihood	0.79	3.72	0.839
Women	Tolterodine	Treatment discontinuation	Country	Restricted maximum likelihood	0.02	0.08	0.781
Women	Tolterodine	Treatment discontinuation	Daily UI	Restricted maximum likelihood	2.04	1.07	0.097
Women	Tolterodine	Treatment discontinuation	Inclusion of minorities	Restricted maximum likelihood	-0.16	0.51	0.759
Women	Tolterodine	Treatment discontinuation	Inclusion of prior failures	Restricted maximum likelihood	-0.35	0.41	0.422
Women	Tolterodine	Treatment discontinuation	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.20	0.26	0.459
Study	Tolterodine	Treatment discontinuation due to adverse effects	Adequacy of randomization	Restricted maximum likelihood	-0.31	0.27	0.278
Study	Tolterodine	Treatment discontinuation due to adverse effects	Allocation concealment	Restricted maximum likelihood	0.36	0.25	0.179
Study	Tolterodine	Treatment discontinuation due to adverse effects	Conflict of interest	Restricted maximum likelihood	1.01	0.40	0.033
Study	Tolterodine	Treatment discontinuation due to adverse effects	Intention to treat analyses	Restricted maximum likelihood	0.30	0.32	0.379
Study	Tolterodine	Treatment discontinuation due to adverse effects	Justification of sample size	Restricted maximum likelihood	-0.46	0.35	0.22
Treatment	Tolterodine	Treatment discontinuation due to adverse effects	Daily dose	Restricted maximum likelihood	-0.49	0.22	0.054
Treatment	Tolterodine	Treatment discontinuation due to adverse effects	Weeks of treatment	Restricted maximum likelihood	0.06	0.08	0.49
Women	Tolterodine	Treatment discontinuation due to adverse effects	% women	Restricted maximum likelihood	0.00	0.03	0.974

Appendix Table F48. Exploring statistical heterogeneity in risk difference by treatment, clinical, or study characteristics with meta-regression (continued)

Diversity factor	Drug	Outcome	Contributing variable	Estimate of between-study variance	Coefficient (absolute risk difference)	Standard error	P value
Women	Tolterodine	Treatment discontinuation due to adverse effects	Control rate	Restricted maximum likelihood	-11.32	3.49	0.01
Women	Tolterodine	Treatment discontinuation due to adverse effects	Country	Restricted maximum likelihood	0.02	0.22	0.945
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of minorities	Restricted maximum likelihood	0.38	0.59	0.535
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of prior failures	Restricted maximum likelihood	0.54	0.62	0.404
Women	Tolterodine	Treatment discontinuation due to adverse effects	Inclusion of women with surgical risk factors for UI	Restricted maximum likelihood	-0.38	0.56	0.514